• Mira Smart Conferencing
  • Home
  • Table of Contents
  • Advanced Search
 
Advanced Search

Browse All

Current Filters

CLEAR FILTER x

TITLE

Author Institution:

  • National Cancer Center, Goyang, Korea, Republic of

Filter

Partial Search: Partial searches may be entered manually by pressing enter in the filter input field.
Author Filter: Selecting one or more Authors from the Author drop down list will filter results by Author last name(s) only.

Displaying 1 - 4 of 4

  • Page:
  • 1

Real-world Clinical Outcomes with Eculizumab and Ravulizumab in Anti-aquaporin-4 Antibody-positive (AQP4-Ab+) Neuromyelitis Optica Spectrum Disorder (NMOSD): Results from the Global NMO SPOTLIGHT Registry

Author:Sotirchos, Elias   Obeidat, Ahmed   Kim, Ho Jin   Nakahara, Jin   Tkachuk, Veronica   Przybyl, Lindsey   Fam, Sami   

Session Name:S6: Autoimmune Neurology: NMOSD and MOGAD  

Topic:Autoimmune Neurology  

Program Number:S6.009  

Author Institution:Johns Hopkins University School of Medicine, Baltimore, MD  Medical College of Wisconsin, Milwaukee, WI  National Cancer Center, Goyang, Korea, Republic of  Keio University School of Medicine, Tokyo, Japan  Instituto de Investigaciones Metabolicas (IDIM), Buenos Aires, Argentina  Alexion, AstraZeneca Rare Disease, Boston, MA  

  • View Abstract
  • View Disclosure

A Comparative Clinical Effectiveness Trial of Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab to Prevent Relapses in Neuromyelitis Optica Spectrum Disorder (NMOSD)

Author:Bilodeau, Philippe-Antoine   Vishnevetsky, Anastasia   Devlin, Michael   Bhattacharyya, Shamik   Salky, Rebecca   Mendoza, Juan Sebastian   Friede, Tim   Bennett, Jeffrey   Cree, Bruce   Palace, Jacqueline   Levy, Michael   Fujihara, Kazuo   Kim, Ho Jin   Flanagan, Eoin   Matiello, Marcelo   Paul, Friedemann   

Session Name:P3: Autoimmune Neurology: NMOSD/MOGAD 3  

Topic:Autoimmune Neurology  

Program Number:P3.001  

Author Institution:Massachusetts General Hospital, Boston, MA  The Sumaira Foundation, Cambridge, MA  Brigham and Women'S Hospital, Boston, MA  Charite-Berlin, Berlin, Germany  University Medical Center Göttingen, Göttingen, Germany  University of Colorado School of Medicine, Aurora, CO  UCSF, Multiple Sclerosis Center, San Francisco, CA  John Radcliff Hospital Oxford Univeristy Hospitals Trust, Oxford, United Kingdom  Massachusetts General Hospital/Harvard Medical School, Boston, MA  Fukushima Medical University School of Medicine, Sendai, Japan  National Cancer Center, Goyang, Korea, Republic of  Mayo Clinic, Rochester, MN  Massachusetts General Hospital, Brigham, Harvard, Boston, MA  Charite Universitatsmedizin in Berlin, Berlin, Germany  

  • View Abstract
  • View Disclosure

Long-term Efficacy and Safety of Ravulizumab in Anti-aquaporin-4 Antibody-positive (AQP4-Ab+) Neuromyelitis Optica Spectrum Disorder (NMOSD): Final Analysis of the Phase 3 CHAMPION-NMOSD Trial

Author:Pittock, Sean   Barnett, Michael   Bennett, Jeffrey   Berthele, Achim   de Sèze, Jérôme   Levy, Michael   Nakashima, Ichiro   Oreja-Guevara, Celia   Palace, Jacqueline   Paul, Friedemann   Pozzilli, Carlo   Allen, Kerstin   Parks, Becky   Kim, Ho Jin   

Session Name:P7: Autoimmune Neurology: NMOSD/MOGAD 6  

Topic:Autoimmune Neurology  

Program Number:P7.012  

Author Institution:Mayo Clinic, Rochester, MN  University of Sydney, Sydney, New South Wales, Australia  University of Colorado, Anschutz Medical Campus, Aurora, CO  School of Medicine and Health, Technical University of Munich, Munich, Germany  University Hospital of Strasbourg, Strasbourg, France  Massachusetts General Hospital and Harvard Medical School, Boston, MA  Tohoku Medical and Pharmaceutical University , Sendai, Japan  San Carlos Clinical Hospital and Complutense University of Madrid, Madrid, Spain  John Radcliff Hospital, Oxford, United Kingdom  Charité-Universitätsmedizin Berlin and Max Delbrück Centre for Molecular Medicine, Berlin, Germany  Sapienza University, Rome, Italy  Alexion, AstraZeneca Rare Disease, Boston, MA  National Cancer Center, Goyang, Korea, Republic of  

  • View Abstract
  • View Disclosure

Blood Levels of Immune Cells, Immunoglobulins, and Platelets in the Phase Three HERCULES and GEMINI Trials of Tolebrutinib in Non-relapsing Secondary Progressive Multiple Sclerosis and Relapsing Multiple Sclerosis

Author:Oreja Guevara, Celia   Bar-Or, Amit   Wiendl, Heinz   Kim, Ho Jin   Syed, Sana   Xu, Zhixing   Vargas, Wendy   Maxwell, Christina   Hincelin-Mery, Agnes   Djukic, Biljana   Turner, Timothy   Oh, Jiwon   Fox, Robert   

Session Name:P9: Multiple Sclerosis: Clinical Trials 2  

Topic:Multiple Sclerosis  

Program Number:P9.001  

Author Institution:Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, Madrid, Spain  University of Pennsylvania, Philadelphia, PA  University of Freiburg, Freiburg im Breisgau, Germany  National Cancer Center, Goyang, Korea, Republic of  Sanofi, Cambridge, MA  Sanofi, Edison, NJ  Sanofi, Bridgewater, NJ  Sanofi, Mullica Hill, NJ  Sanofi, Vitry Sur Seine, France  St Michael's Hospital, Toronto, ON, Canada  Cleveland Clinic, Cleveland, OH  

  • View Abstract
  • View Disclosure

Displaying 1 - 4 of 4

  • Page:
  • 1

© 2015 Mira Smart Conference | http://www.mirasmart.com